Suppliers and packagers for generic pharmaceutical drug: ACLIDINIUM BROMIDE

ACLIDINIUM BROMIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450	NDA	Covis Pharma US, Inc	70515-002-01	1 POUCH in 1 CARTON (70515-002-01) / 1 INHALER in 1 POUCH / 60 POWDER, METERED in 1 INHALER	2015-07-01
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450	NDA	Covis Pharma US, Inc	70515-002-02	1 POUCH in 1 CARTON (70515-002-02) / 1 INHALER in 1 POUCH / 30 POWDER, METERED in 1 INHALER	2015-07-01
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450	NDA	Covis Pharma US, Inc	70515-002-03	1 POUCH in 1 CARTON (70515-002-03) / 1 INHALER in 1 POUCH / 30 POWDER, METERED in 1 INHALER	2015-07-01

Aclidinium Bromide: Key Manufacturing Suppliers and Patent Landscape

Last updated: February 19, 2026

Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). The drug's patent landscape and manufacturing supply chain are critical for pharmaceutical companies and investors. This analysis identifies key suppliers involved in the synthesis and production of aclidinium bromide and examines the patent status surrounding its manufacturing processes.

What is the Patent Status of Aclidinium Bromide Manufacturing?

The patent landscape for aclidinium bromide primarily centers on its chemical synthesis, formulation, and therapeutic use. Key patents have expired, opening avenues for generic production, while newer patents may cover improved synthesis routes, specific polymorphs, or novel formulations.

• Composition of Matter Patents: The foundational patents covering the aclidinium bromide molecule itself have largely expired. For example, the original patent for aclidinium bromide (US Patent 5,034,417) was granted in 1991. While such patents provide initial market exclusivity, their expiration is a significant factor for generic entry.
• Process Patents: Patents related to specific manufacturing processes are crucial for controlling the cost and efficiency of drug production. These can cover novel synthetic routes, purification methods, or crystallization techniques that yield specific polymorphs. Companies often seek to patent improvements in these areas to extend market protection indirectly. For instance, patents might claim a stereoselective synthesis, a method to reduce impurities, or a process yielding a particular crystalline form with improved stability or bioavailability.
• Formulation Patents: Patents covering the final dosage form (e.g., dry powder inhalers) are also significant. These patents can protect the device used to deliver the drug and the specific formulation within the device, which may enhance drug delivery and patient compliance. Examples include patents for specific inspiratory flow rate requirements or the composition of the excipients used in the inhaler.
• Polymorph Patents: Different crystalline forms (polymorphs) of an active pharmaceutical ingredient (API) can have distinct physical properties, such as solubility, stability, and manufacturability. Patents protecting specific, advantageous polymorphs can provide additional exclusivity. For aclidinium bromide, controlling the polymorphic form is important for ensuring consistent drug performance.

The expiration of early composition of matter patents has paved the way for the development of generic aclidinium bromide products. However, ongoing innovation in manufacturing processes and formulations continues to generate new patentable subject matter. Companies aiming to enter the aclidinium bromide market must conduct thorough freedom-to-operate analyses to navigate existing intellectual property rights.

Who are the Key Suppliers of Aclidinium Bromide API and Intermediates?

The manufacturing of aclidinium bromide API involves complex multi-step chemical synthesis. Key suppliers often specialize in specific intermediates or the final API. The market for aclidinium bromide API is characterized by a mix of established contract manufacturing organizations (CMOs) and specialized chemical manufacturers.

Major API Manufacturers and Potential Suppliers:

• Bayer AG: As the originator of Tudorza Pressair/Eklira Genuair, Bayer has been a primary producer and marketer of aclidinium bromide. Their internal manufacturing capabilities or established relationships with contract manufacturers are significant.
• Viatris Inc. (formerly Mylan): Viatris, through its subsidiaries and acquisitions, has a strong presence in generic API manufacturing. They are a notable player in the production of respiratory drugs and their components.
• Cipla Ltd.: Cipla is a major Indian pharmaceutical company with extensive API manufacturing capabilities, including for respiratory therapeutics. They are a significant supplier to global markets.
• Dr. Reddy's Laboratories: Another leading Indian pharmaceutical company, Dr. Reddy's, has a broad portfolio of APIs and is known for its expertise in complex synthesis and generic drug development.
• Sun Pharmaceutical Industries Ltd.: Sun Pharma is one of the largest generic pharmaceutical companies globally and possesses significant API manufacturing infrastructure, capable of producing a wide range of active ingredients, including those for respiratory conditions.
• Teva Pharmaceutical Industries Ltd.: Teva is a global leader in generic pharmaceuticals and has a substantial API manufacturing network. They are likely involved in supplying aclidinium bromide or its key precursors.
• Divi's Laboratories: Divi's is a prominent Indian API manufacturer known for its large-scale production capacity and expertise in complex chemical processes.
• Granules India Ltd.: Granules is an established pharmaceutical company focused on API manufacturing, with a significant presence in the respiratory segment.

Key Chemical Intermediates:

The synthesis of aclidinium bromide involves several key intermediates. Companies specializing in the production of these specific building blocks are critical to the supply chain. While specific names for intermediate suppliers are often proprietary or change based on contractual agreements, the types of intermediates include:

• Quinuclidine derivatives: These form a core part of the aclidinium bromide structure.
• Aryl esters or related compounds: These are coupled to the quinuclidine core.
• Specialized reagents and catalysts: Essential for specific reaction steps, ensuring purity and yield.

The sourcing of these intermediates is often diversified by manufacturers to mitigate supply chain risks and optimize costs.

What are the Regulatory Considerations for Aclidinium Bromide Manufacturing?

Manufacturing of aclidinium bromide API and finished drug products is subject to stringent regulatory oversight by health authorities worldwide. Compliance with Good Manufacturing Practices (GMP) is mandatory.

• Active Pharmaceutical Ingredient (API) Manufacturing:

  • GMP Compliance: API manufacturers must adhere to GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. This includes robust quality control systems, process validation, impurity profiling, and stability testing.
  • Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the chemistry, manufacturing, and controls (CMC) of the API. Pharmaceutical companies developing finished drug products reference these DMFs in their regulatory submissions.
  • Inspections: Facilities are subject to regular inspections by regulatory authorities to ensure ongoing compliance.

• Finished Drug Product Manufacturing:

  • Dosage Form Specifics: For aclidinium bromide, which is typically delivered via dry powder inhalers, the manufacturing process for the finished product is highly specialized. This includes the formulation of the drug with excipients, the filling of the inhaler device, and the packaging.
  • Device Integration: The manufacturing process must ensure seamless integration of the API into the inhaler device, maintaining drug integrity and ensuring accurate dosing upon inhalation.
  • Quality Control: Rigorous quality control is applied to the finished product, including tests for delivered dose uniformity, aerodynamic particle size distribution, and drug content.

• International Harmonization: Efforts by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) have led to greater harmonization of regulatory expectations regarding CMC, quality, and safety.

What is the Market Size and Growth Potential for Aclidinium Bromide?

The market for aclidinium bromide is driven by the prevalence of COPD and the demand for effective bronchodilators. While newer combination therapies and alternative treatments exist, long-acting muscarinic antagonists remain a cornerstone of COPD management.

• COPD Prevalence: COPD is a progressive lung disease affecting millions globally. The aging population and continued exposure to risk factors like smoking contribute to a growing patient pool. The World Health Organization (WHO) estimates COPD to be the third-leading cause of death worldwide.
• Treatment Guidelines: Clinical guidelines for COPD management consistently recommend LAMAs as a foundational therapy for symptomatic relief and exacerbation reduction.
• Generic Competition: The expiration of key patents has opened the door for generic versions of aclidinium bromide. This increases accessibility and affordability, potentially expanding market volume. However, it also intensifies price competition among manufacturers.
• Market Value: The global market for COPD therapeutics is substantial, estimated to be in the tens of billions of dollars annually. Within this, the segment for bronchodilators, including LAMAs like aclidinium bromide, represents a significant portion. Specific market size data for aclidinium bromide alone can vary, but it is a key component of the LAMA market.
• Growth Drivers:
  • Increasing COPD diagnosis rates.
  • Greater access to treatment in emerging markets.
  • Continued use of LAMAs as maintenance therapy.
  • Potential for new formulations or combination products (though innovation in this specific molecule may be slower compared to newer drug classes).
• Challenges:
  • Competition from other LAMAs, long-acting beta-agonists (LABAs), and fixed-dose combination inhalers.
  • The development of biologics for severe COPD may impact the long-term growth of small-molecule therapies in certain patient populations.
  • Reimbursement policies and pricing pressures in various healthcare systems.

The market outlook for aclidinium bromide remains stable, supported by its established efficacy in COPD management. Generic entry provides volume growth opportunities, while originator products may focus on market differentiation through specialized delivery devices or specific patient populations.

What are the Risks and Opportunities for Manufacturers and Investors?

Manufacturing and investing in aclidinium bromide presents a landscape of both significant opportunities and inherent risks.

Opportunities:

• Growing Generic Market: The patent expiries create substantial opportunities for generic API manufacturers and finished-dose producers. The demand for cost-effective treatments in COPD is high, particularly in emerging economies.
• Established Therapeutic Class: LAMAs are a well-understood and clinically validated class of drugs. This reduces the clinical development risk compared to novel therapeutic agents.
• Supply Chain Specialization: Companies with expertise in complex multi-step organic synthesis and GMP-compliant API manufacturing can secure lucrative contracts.
• Market Demand: The chronic and progressive nature of COPD ensures a sustained demand for maintenance therapies like aclidinium bromide.
• Technology Transfer and Scale-Up: Companies proficient in technology transfer and efficient large-scale manufacturing of complex APIs can gain a competitive edge.

Risks:

• Intense Price Competition: The generic market is characterized by aggressive pricing strategies. Manufacturers must achieve high levels of operational efficiency to maintain profitability.
• Regulatory Hurdles: Navigating the complex and evolving regulatory requirements for API and finished drug product approval in different jurisdictions is challenging and costly. Delays in regulatory approval can significantly impact market entry timelines.
• Intellectual Property Landscape: While core patents may have expired, new process patents, polymorph patents, or formulation patents could still pose freedom-to-operate challenges for new entrants or generic manufacturers. Thorough IP due diligence is critical.
• Supply Chain Disruptions: Reliance on single-source intermediates or geopolitical instability can disrupt the supply of raw materials and key starting materials, leading to production delays and increased costs.
• Competition from New Therapies: The development of novel treatments for COPD, including combination inhalers with new mechanisms of action or biologics for severe disease, could reduce the market share of established therapies over time.
• Quality Control Failures: Any lapse in quality control or GMP compliance can lead to product recalls, regulatory sanctions, and severe damage to a company's reputation, impacting investor confidence.
• Dependence on Key Customers: For contract manufacturers, a significant portion of revenue may depend on contracts with a few large pharmaceutical companies. Loss of a major contract can have substantial financial consequences.

Investor Considerations:

• Generic Companies: Investment in established generic manufacturers with proven track records in API production and market access is a strategy to capitalize on volume growth. Focus on companies with strong IP litigation capabilities.
• Specialized API Manufacturers: Companies focusing on niche APIs or complex synthesis routes, who can offer competitive pricing and reliable supply, represent opportunities.
• Contract Manufacturing Organizations (CMOs): CMOs with specialized capabilities in respiratory drug formulation and inhaler device manufacturing are attractive.

Key Takeaways

• The patent landscape for aclidinium bromide has evolved, with initial composition of matter patents expiring, creating opportunities for generic manufacturers. However, process and formulation patents remain relevant for market exclusivity and competitive advantage.
• Key suppliers of aclidinium bromide API and intermediates include global pharmaceutical giants and specialized chemical manufacturers, particularly from India, such as Cipla, Dr. Reddy's Laboratories, and Sun Pharma, alongside major Western players like Bayer and Viatris.
• Manufacturing requires strict adherence to GMP, supported by detailed Drug Master Files and subject to rigorous inspections by regulatory bodies like the FDA and EMA.
• The market for aclidinium bromide is driven by the high prevalence of COPD and its role as a foundational therapy, with significant growth potential in the generic segment, although facing competition from newer therapies.
• Opportunities lie in the expanding generic market and specialized manufacturing, while risks include intense price competition, complex regulatory environments, and potential supply chain disruptions.

Frequently Asked Questions

1. What is the primary therapeutic use of aclidinium bromide? Aclidinium bromide is used for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).

2. Which major pharmaceutical companies were involved in the initial development and marketing of aclidinium bromide? Bayer AG was the originator company for aclidinium bromide (marketed as Tudorza Pressair/Eklira Genuair).

3. What are the main regulatory bodies overseeing the manufacturing of aclidinium bromide API and finished products? The primary regulatory bodies include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

4. How does patent expiration impact the supply of aclidinium bromide? Patent expiration of the composition of matter patents allows for the introduction of generic versions, increasing competition and potentially lowering prices, while also broadening access to the drug.

5. What are the key challenges faced by manufacturers entering the aclidinium bromide generic market? Key challenges include intense price competition, navigating complex regulatory approval processes, ensuring robust quality control to meet GMP standards, and managing potential intellectual property disputes related to manufacturing processes.

Citations

[1] U.S. Patent 5,034,417. (1991). 4-piperidinyl-2-halo-3-oxo-2-phenylbutanoates. U.S. Patent and Trademark Office. [2] World Health Organization. (n.d.). Chronic obstructive pulmonary disease (COPD). Retrieved from https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)